Three Analyst Firms Start Greenway (GWAY) at Buy, Two at Neutral

A number of analyst firms have initiated coverage on shares of Greenway Medical Tech (NYSE: GWAY) Tuesday morning:

• Morgan Stanley with an Equalweight rating
  
• JPMorgan with an Overweight and $19 price target
  
• Piper Jaffray with a Neutral and $15 target
  
• William Blair with an Outperform
  
• Raymond James with an Outperform rating and a $17.50 target

Check out our Ratings Insider portal to get the most comprehensive and up-to-date analyst coverage on the Street.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Lyntris files for IPO, plans to list on NYSE under "LYNX"
• Reformation files for 14.06M share IPO on NYSE at $15-$17 per share
• Reformation launches IPO on NYSE at $15-$17 per share